Research Shows TSH Use Should be Scaled Back to a Supporting Role When Treating Thyroid Patients

The way TSH is currently used by endocrinologists and doctors treating thyroid patients is wrong.

The way people are treated, as if they are all the same is wrong, and simply being ‘in range’ on levothyroxine monotherapy is not going to guarantee a good outcome.

I include two research papers in this blog post.

This piece of research is undoubtedly one of the most important studies done in the last ten years.

It finally begins to be more clear that TSH is one of the least useful tools in assessing thyroid hormone levels and whether someone is actually getting enough T3 in the cells:

“Homeostatic Control of the Thyroid-Pituitary Axis: Perspectives for Diagnosis and Treatment.”
Hoermann, Midgley, Larisch, Dietrich.
Front Endocrinol 2015 Nov 20;6:177. doi: 10.3389/fendo.2015.00177.
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/26635726
Full Article: 
https://www.frontiersin.org/articles/10.3389/fendo.2015.00177/full


This second research paper concludes that getting TSH into the reference range is no guarantee of good health. It shows how simplistically and poorly TSH is being used today. TSH is not something that should be relied upon in the way it is being done at the present time:

“TSH Measurement and Its Implications for Personalised Clinical Decision-Making”
Rudolf Hoermann and John E. M. Midgley
Volume 2012 Article ID 438037  https://doi.org/10.1155/2012/438037
https://www.hindawi.com/journals/jtr/2012/438037/ 

Best wishes,

Paul

Paul Robinson

Paul Robinson is a British author and thyroid patient advocate. The focus of his books and work is on helping patients recover from hypothyroidism. Paul has accumulated a wealth of knowledge on thyroid and adrenal dysfunction and their treatment. His three books cover all of this.

Like this post? Then why not share or print it using the buttons below:

Leave a Comment